Isotechnika Pharma's Phase III uveitis study fails to meet primary endpoint Equities.com Our emphasis on nephrology remains intact and we continue to have full confidence in the potential of voclosporin to address significant unmet medical needs like kidney transplant rejection and lupus nephritis." http://www.datamonitor.com Republication ... |
